Topic: Cholesterol - Primary Care
Tuesday, 11 April 2017
Detailed results from the FOURIER cardiovascular outcomes trial on evolocumab were presented at a late-breaking oral presentation at the American College of Cardiology meeting in Washington DC recently. This is the first major outcomes study to be published for a PCSK9 inhibitor – a new class of cholesterol-lowering medicines.
Wednesday, 04 January 2017
Adding evolocumab to optimised statin therapy results in statistically significant regression of atherosclerosis in patients with coronary artery disease, according to results from the GLAGOV phase 3 trial.
Monday, 20 March 2017
The British Heart Foundation is pressing for a renewed focus on improving the diagnosis and management of familial hypercholesterolaemia, and adoption of a nationwide cascade screening programme for first-degree relatives. The article includes best practice tips for busy primary healthcare professionals.
Sunday, 12 March 2017
Recently announced results from the FOURIER trial show that treatment with the PCSK9 inhibitor evolocumab significantly reduced the risk of cardiovascular events in patients with clinical atherosclerotic cardiovascular disease on optimized statin therapy.
Category: Have You Heard
Thursday, 04 October 2018
A recent study from Finland shows that children with serum 25-hydroxyvitamin D levels >80 nmol/l had lower plasma total and LDL cholesterol levels than children whose serum 25-hydroxyvitamin D levels were
Friday, 30 June 2017
The leading UK cardiovascular conference for the whole primary care team. Expert presenters and a down-to-earth approach help health professionals translate the latest evidence into daily practice and optimise patient care. Participants also receive 9 hours CPD credits. Book now to attend this inspirational event and take advantage of our Early Bird discount.
Thursday, 27 October 2016
The benefits of statin therapy have been repeatedly underestimated, and the harms exaggerated, due to misinterpretation of the evidence, according to the authors of a major review published in The Lancet recently.
Monday, 12 September 2016
The European Atherosclerosis Society has conducted a survey to assess the general public’s understanding of cholesterol. Professor Mike Kirby summarizes the survey findings and highlights the importance of a clear and constant focus on the JBS3 2014 consensus recommendations.
Monday, 12 September 2016
Two injectable antibody-based therapies inhibiting the activity of PCSK9 - alirocumab and evolucumab - have recently been licensed. This paper reviews the current status of lipid management, the actions of PCSK9, and the clinical trial results achieved with PCSK9 inhibitors in early studies.
Tuesday, 05 October 2010